Author

Mahan Moshir

Observed names: M. Moshir, Moshir, Mahan

ORCID: 0009-0009-0287-1049

Observed ORCID: 0009-0009-0287-1049

OpenAlex ID: A5073344530

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

2020 · Carsten Riether, Thomas Pabst, et al. · Nature Medicine · 216

Highly efficient peptide separations in proteomics

2007 · Koen Sandra, Mahan Moshir, et al. · Journal of Chromatography B · 116

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

2013 · Karen Silence, Torsten Dreier, et al. · mAbs · 106

PDF

Highly efficient peptide separations in proteomicsPart 2: Bi- and multidimensional liquid-based separation techniques

2009 · Koen Sandra, Mahan Moshir, et al. · Journal of Chromatography B · 103

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

2017 · Philippe Aftimos, Christian Rolfo, et al. · Clinical Cancer Research · 69

Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

2021 · Nicolas Leupin, Pier Luigi Zinzani, et al. · Cancer · 38

A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo

2013 · Johannes Trebing, Isabell Lang, et al. · mAbs · 29

PDF

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

2018 · Adrian F Ochsenbein, Carsten Riether, et al. · Blood · 22

Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models

2025 · Prajakta Warang, Gagandeep Singh, et al. · Human Vaccines & Immunotherapeutics · 15

A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.

2014 · Ahmad Awada, Christian D. Rolfo, et al. · Journal of Clinical Oncology · 13

Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans

2019 · Adrian F Ochsenbein, Thomas Pabst, et al. · Blood · 12

Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys

2025 · Ornella Binazon, Mario Cocco, et al. · Journal of Immunotoxicology · 9

PDF

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

2019 · Carsten Riether, Tanja Chiorazzo, et al. · Blood · 8

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

2018 · Martine Bagot, Marie Maerevoet, et al. · Blood · 7

Cd70 Expression in Cutaneous T Cell Lymphoma (ctcl) Patients and Mechanisms of Action of Argx‐110 in Skin: Histopathological and Clinical Data

2017 · A. Hultberg, D. Gandini, et al. · Hematological Oncology · 5

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.

2016 · Jean-Marie Michot, Marie Maerevoet, et al. · Journal of Clinical Oncology · 4

Prevalance Rate of Different Types of Yeast Infection in Patients Visiting the Dermatology Clinic of Hazrat Rasul-e Akram Hospital

2002 · A Tabatabai, M Poureslami, et al. · مجله علوم پزشکی رازی · 2

Anti-C2–mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis

2026 · Britt Arets, Siyang Peng, et al. · Journal of Translational Autoimmunity

PDF

Optimization of the Cell‐Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis Patients

2026 · Peng Du, Marina Mané‐Damas, et al. · Muscle & Nerve

Efgartigimod is a Unique FcRn Blocker That Allows IgG Reduction Without Broad Inhibition of Immune Responses (P3-2.008)

2026 · Sophie Steeland, Kristin Heerlein, et al. · Neurology

Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod

2026 · Fatemeh Khani-Habibabadi, Fien M Verhamme, et al. · Journal of Neurology Neurosurgery & Psychiatry

Supplementary methods from Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

2023 · Philippe Aftimos, Christian Rolfo, et al.

Data from Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

2023 · Philippe Aftimos, Christian Rolfo, et al.

A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody (TM) ARGX-110

2016 · Jean‐Marie Michot, Karen Silence, et al. · Ghent University Academic Bibliography (Ghent University)

Abstract 5470: Pre-clinical characterization of ARGX-110: A neutralizing, humanized monoclonal antibody to the human CD70 antigen with enhanced ADCC properties.

2013 · Karen Silence, Hans De Haard, et al. · Cancer Research

Works count: 31

Citation count: 774

H-index: 11

I10-index: 11